SCHEMBL23949875

SCHEMBL23949875

CC(C)(C)OC(=O)NCc1ccc(-c2ncc(C#N)cc2F)nc1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.42
EGLN2 Q96KS0 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
IRAK4 Q9NWZ3 2/20 0.39
TNF P01375 2/20 0.39
ATR Q13535 1/20 0.39
NAMPT P43490 1/20 0.38
GRM2 Q14416 1/20 0.38
DYRK1A Q13627 1/20 0.37
HDAC1 Q13547 2/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
PRKAA2 P54646 1/20 0.37
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20176789 0.81 EGLN2 (0.49) NSD2EGLN2L3MBTL1ATRGRM2
SCHEMBL30751802 0.81 EGLN2 (0.49) NSD2EGLN2L3MBTL1ATRGRM2
SCHEMBL23949874 0.76 NSD2 (0.39) NSD2IRAK4TNFNAMPTHDAC1
SCHEMBL2586677 0.76 L3MBTL1 (0.52) NSD2L3MBTL1NAMPTDYRK1AHDAC1
SCHEMBL30686739 0.76 DYRK1A (0.42) L3MBTL1ATRNAMPTGRM2DYRK1A
SCHEMBL26943225 0.76 DYRK1A (0.42) L3MBTL1ATRNAMPTGRM2DYRK1A
Hydrochloric Acid SCHEMBL6969707 0.75 L3MBTL1 (0.51) NSD2L3MBTL1NAMPTDYRK1AHDAC1
SCHEMBL25162015 0.74 NAMPT (0.50) L3MBTL1ATRNAMPTDYRK1AHDAC1
SCHEMBL29859843 0.74 L3MBTL1 (0.52) L3MBTL1NAMPTGRM2DYRK1AHDAC1
SCHEMBL3274015 0.74 EPHX2 (0.58) L3MBTL1NAMPTHDAC1CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2023-06-01 US disclosed
CN-115996910-A Aryl or heteroaryl derivatives 帝人制药株式会社 2023-04-21 CN disclosed
EP-4137481-A1 ARYL OR HETEROARYL DERIVATIVE Teijin Pharma Limited (JP) 2023-02-22 EP disclosed
EP-4137481-A1 ARYL OR HETEROARYL DERIVATIVE Teijin Pharma Limited (JP) 2023-02-22 EP disclosed
WO-2021210650-A1 ARYL OR HETEROARYL DERIVATIVE 帝人ファーマ株式会社 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167073-A1 ARYL OR HETEROARYL DERIVATIVE ARRB1, NR3C2, TRPC6 NSD2 3265/4885EGLN2 3919/4885L3MBTL1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.